ARTICLE | Clinical News
PT1: Phase I data
June 28, 2010 7:00 AM UTC
In a Phase I trial in 46 healthy volunteers, PT1.2 was well tolerated at 2 dose levels with no safety issues reported. Additional data will be presented at the Interscience Conference on Antimicrobial...